The Motley Fool Podcasts Industry Focus Healthcare: Pfizer Takes Aim At Regeneron, And UnitedHealth's Earnings Update

Healthcare: Pfizer Takes Aim At Regeneron, And UnitedHealth's Earnings Update Logo

Healthcare: Pfizer Takes Aim At Regeneron, And UnitedHealth's Earnings Update

Pfizer's latest phase 3 trial results put its promising eczema drug on a path to challenge Regeneron and Sanofi's $2 billion-per-year drug, Dupixent. Also, how Regenxbio and Adverum Biotechnologies hope to change how a we treat a common cause of vision loss in seniors, and why United Healthcare's latest quarterly results sent shares soaring.

Check out more of our content here:

Listen to Healthcare: Pfizer Takes Aim At Regeneron, And UnitedHealth's Earnings Update

Recent Episodes

Listen
Listen
Listen
Listen
Listen